KeyCorp upgraded shares of Rapid Micro Biosystems (NASDAQ:RPID - Free Report) to a strong-buy rating in a report issued on Tuesday,Zacks.com reports. KeyCorp also issued estimates for Rapid Micro Biosystems' FY2024 earnings at ($1.10) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.97) EPS and FY2026 earnings at ($0.82) EPS.
Rapid Micro Biosystems Stock Performance
RPID stock traded down $0.09 during trading on Tuesday, hitting $3.48. 551,651 shares of the company's stock traded hands, compared to its average volume of 426,841. The stock has a market capitalization of $149.76 million, a price-to-earnings ratio of -3.11 and a beta of 1.26. Rapid Micro Biosystems has a 52 week low of $0.58 and a 52 week high of $3.75. The business has a fifty day simple moving average of $1.50 and a 200 day simple moving average of $1.13.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in shares of Rapid Micro Biosystems by 122.9% during the 4th quarter. Renaissance Technologies LLC now owns 183,087 shares of the company's stock worth $165,000 after acquiring an additional 100,942 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Rapid Micro Biosystems in the fourth quarter worth $65,000. Finally, Millennium Management LLC lifted its position in shares of Rapid Micro Biosystems by 17.6% during the fourth quarter. Millennium Management LLC now owns 61,375 shares of the company's stock worth $55,000 after purchasing an additional 9,191 shares during the last quarter. Institutional investors own 52.60% of the company's stock.
Rapid Micro Biosystems Company Profile
(
Get Free Report)
Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Further Reading
Before you consider Rapid Micro Biosystems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapid Micro Biosystems wasn't on the list.
While Rapid Micro Biosystems currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
